Subscribe To
DCPH / Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
![Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues](https://cdn.snapi.dev/images/v1/l/x/283-2017235.jpg)
DCPH News
![Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat](https://cdn.snapi.dev/images/v1/f/h/54491-2130334.jpg)
By Zacks Investment Research
October 31, 2023
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sa more_horizontal
![Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates](https://cdn.snapi.dev/images/v1/d/u/default45-2128081.jpg)
By Zacks Investment Research
October 30, 2023
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This more_horizontal
![Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals: Clawing Its Way Back](https://cdn.snapi.dev/images/v1/y/h/image-1431995791-2031808.jpg)
By Seeking Alpha
August 22, 2023
Deciphera Pharmaceuticals: Clawing Its Way Back
Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. more_horizontal
![3 Under-the-Radar Biotech Stocks to Buy in 2023 3 Under-the-Radar Biotech Stocks to Buy in 2023](https://cdn.snapi.dev/images/v1/p/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7443232fhealthcare-lab-treatment-research-scientist-1jpgopresizew400h400-2029740.jpg)
By The Motley Fool
August 19, 2023
3 Under-the-Radar Biotech Stocks to Buy in 2023
Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a par more_horizontal
![Why Shares of Deciphera Pharmaceuticals Rose This Week Why Shares of Deciphera Pharmaceuticals Rose This Week](https://cdn.snapi.dev/images/v1/r/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7438722fpatient-checking-in-for-a-doctors-appointmentjpgopresizew400h400-2020123.jpg)
By The Motley Fool
August 11, 2023
Why Shares of Deciphera Pharmaceuticals Rose This Week
Deciphera saw revenue rise by 17.4% year over year. The company's only marketed therapy is Qinlock to treat advanced GIST. more_horizontal
![Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues](https://cdn.snapi.dev/images/v1/l/x/283-2017235.jpg)
By Zacks Investment Research
August 10, 2023
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales. more_horizontal
![Deciphera Is A Buy In Expectation Of A Significant Comeback Deciphera Is A Buy In Expectation Of A Significant Comeback](https://cdn.snapi.dev/images/v1/j/k/image-1386963131-1938656.jpg)
By Seeking Alpha
June 18, 2023
Deciphera Is A Buy In Expectation Of A Significant Comeback
After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current pric more_horizontal
![Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference](https://cdn.snapi.dev/images/v1/i/0/conf18-1876592.jpg)
By Business Wire
May 8, 2023
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and c more_horizontal